Gossamer Bio, Inc. (FRA:4GB)

Market Cap	74.85M -54.4%
Revenue (ttm)	41.28M -57.7%
Net Income	-145.10M
EPS	-0.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.3348
Previous Close	0.3366
Day's Range	0.3348 - 0.3348
52-Week Range	0.2732 - 3.1740
Beta	n/a
RSI	38.59
Earnings Date	May 7, 2026

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 162
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4GB

Financial Performance

In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.

Financial numbers in USD